(Q34481761)

2 August 2017

1 reference

title

New developments in psychopharmacology of attention deficit hyperactivity disorder (English)

1 reference

attention deficit hyperactivity disorder

2 August 2017

1 reference

1 reference

Pliszka SR

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

published in

1 reference

2 August 2017

volume

10

1 reference

2 August 2017

issue

10

1 reference

2 August 2017

page(s)

1797-1807

1 reference

A review of stimulant drug research with hyperactive children

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

Methyiphenidate vs. amphetamine: Comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

Impact of tic disorders on ADHD outcome across the life cycle: findings from a large group of adults with and without ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

More Frequent Diagnosis of Attention Deficit–Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

Uptake of (3H)-catecholamines by homogenates of rat corpus striatum and cerebral cortex: effects of amphetamine analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

Drug interactions with brain biogenic amines and the effects of amphetamine isomers on locomotor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Clinical and biochemical findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

Sudden death in children receiving Norpramin: a review of three reported cases and commentary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

Catecholamines in attention-deficit hyperactivity disorder: current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

Pregnancy, delivery and infancy complications and attention deficit hyperactivity disorder: Issues of gene-environment interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1797

10.1517/13543784.10.10.1797

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference